Business Context and Reporting Period
Company: Neuralstem, Inc. (Note: Metadata listed "Palisade Bio," but filing text confirms Neuralstem, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Neuralstem is a clinical-stage biotechnology company focused on developing treatments based on human neural stem cells and small molecule compounds. The company has no commercial revenue and relies on external financing. Key activities include a Phase I clinical trial for Amyotrophic Lateral Sclerosis (ALS) and pre-clinical development for spinal cord injury and depression.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(11,718,301) | $(2,283,769) |
| Net Loss Per Share (Basic & Diluted) | $(0.29) | $(0.07) |
| Operating Expenses | $7,811,952 | $5,636,208 |
| Cash and Cash Equivalents (End of Period) | $14,025,745 | $3,218,321 |
| Net Cash Used in Operating Activities | $(4,878,730) | $(2,528,276) |
| Net Cash Provided by Financing Activities | $16,713,585 | $903,391 |
| Warrant Liability (Current) | $2,189,064 | $0 |
Liquidity: The company reported a monthly cash burn rate of approximately $900,000. Management estimates sufficient cash to fund operations into the third quarter of 2011.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $9.4 million (317%) compared to the prior year period. This was driven by increased R&D costs for the ALS clinical trial, higher legal fees, and significant non-cash expenses related to warrant accounting.
- Warrant Accounting Impact: The company recorded a $2.0 million loss on the change in fair value of warrant obligations and a $1.9 million warrant issuance/modification expense. In the prior year, the company recorded a $3.3 million gain on warrant obligations.
- Operating Expenses: R&D expenses increased 56% to $4.5 million, primarily due to the initiation of the ALS clinical trial in January 2010. G&A expenses increased 20% to $3.2 million due to legal fees and share-based compensation.
- Cash Position: Cash balances increased by $10.8 million (336%) due to a registered direct offering in June 2010 (gross proceeds ~$10 million) and the exercise of various investor warrants.
Guidance, Outlook, and Risks
Outlook: The company does not anticipate any revenue for 2010. The primary focus remains on the ALS Phase I trial (5 patients dosed as of June 30, 2010) and preparing an IND for Spinal Cord Injury. A subsidiary in China is expected to be formed in Q3 2010.
Capital Needs: The company will require additional capital to sustain operations and clinical trials. It has exhausted its shelf registration statement and anticipates filing a new one. Failure to secure financing could force delays or elimination of development programs.
Risks and Contingencies:
- Clinical Trial Risk: Success is not guaranteed; failure to demonstrate safety or efficacy would materially harm the business.
- Legal Proceedings: Ongoing patent litigation with StemCells, Inc. regarding stem cell culture compositions. The outcome is uncertain and could be costly.
- Warrant Liability: Fluctuations in stock price directly impact the fair value of warrant liabilities, causing volatility in reported earnings.
- Regulatory Risk: Dependence on FDA approval for biologics license applications (BLA) and INDs.
Investor Verification Checklist
- Cash Runway: Verify the $900,000 monthly burn rate against current cash balances to confirm the Q3 2011 liquidity estimate.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the $2.2 million warrant liability and future non-cash charges.
- Clinical Trial Progress: Monitor the safety data and enrollment status of the ALS Phase I trial (currently 5 patients dosed).
- Legal Status: Review updates on the patent infringement litigation with StemCells, Inc.
- Financing Plans: Confirm the timeline for the new shelf registration statement to ensure future capital access.